Arcutis Biotherapeutics, Inc.
ARQT
株式のランク
#4010
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
株価
$32.29
最終同期: 2026-10-19
時価総額
$4.06B
変化（1日）
12.02%
変化（1年）
54.62%
国
US
取引 Arcutis Biotherapeutics, Inc. (ARQT)
カテゴリー
Healthcare
Arcutis Biotherapeutics, Inc.（ARQT）の利益
Jun 2026 時点の利益 TTM: $29.30M
Arcutis Biotherapeutics, Inc. の最新の財務報告によると、同社の現在の利益は $29.30M です。2023 年には $-259.03M の利益を上げ、これは 2022 年の利益 $-311.46M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Arcutis Biotherapeutics, Inc. の利益の推移（2017 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $29.30M | -121.02% |
| 2024 | $-139.39M | -46.19% |
| 2023 | $-259.03M | -16.83% |
| 2022 | $-311.46M | 50.93% |
| 2021 | $-206.36M | 52.09% |
| 2020 | $-135.68M | 223.07% |
| 2019 | $-42.00M | 118.10% |
| 2018 | $-19.26M | 286.80% |
| 2017 | $-4.98M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | 17,904.30% |
US
|
|
| $-3.09B | -10,636.56% |
US
|
|
| $-4.02B | -13,808.09% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 6,557.96% |
NL
|
